Find in Library
Search millions of books, articles, and more
Indexed Open Access Databases
COVID-19 infection during blinatumomab therapy: Is safety a dilemma?
oleh: Julián E Barahona-Correa, Camilo Rueda-Ortiz, María-José López, Sandra Gualtero, Mónica Arevalo-Zambrano
Format: | Article |
---|---|
Diterbitkan: | SAGE Publishing 2023-01-01 |
Deskripsi
Patients with acute lymphoblastic leukemia may be particularly vulnerable to SARS-CoV-2 infection and severe illness. The mainstay of current treatment is the use of blinatumomab in patients with refractory or relapsed B-cell precursor acute lymphoblastic leukemia. We discuss the case of a patient with relapsed acute lymphoblastic leukemia who became positive for SARS-CoV-2 during blinatumomab therapy. There are no formal recommendations on the decision to continue, withhold, or delay blinatumomab treatment in these patients. More studies exploring this issue are warranted, as SARS-CoV-2 is expected to be here to stay.